HORMONE RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cancers: XB010 trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for any side effects. About 396 adults with…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 26, 2026 02:25 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BG-68501 begins
Disease control Recruiting nowThis early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 02:23 UTC
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
New hope for advanced breast cancer: EP0062 trial begins
Disease control Recruiting nowThis study tests a new drug called EP0062 in people with advanced breast cancer that has come back after treatment. The goal is to find the best dose and see if it is safe and works, either alone or with other standard treatments. About 95 adults with a specific type of breast ca…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated May 26, 2026 02:16 UTC
-
New study aims to find best Pre-Surgery hormone treatment for men with breast cancer
Disease control Recruiting nowThis study tests different hormone therapies in men with breast cancer before surgery to see which works best. About 60 men with hormone receptor-positive breast cancer will receive tamoxifen, anastrozole, or anastrozole plus degarelix, with or without abemaciclib. The goal is to…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jose Pablo Leone • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
Promising drug cocktail aims to stop breast cancer recurrence
Disease control Recruiting nowThis study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
New Triple-Drug attack on Hard-to-Treat breast cancer shows promise
Disease control Recruiting nowThis study tests a new three-drug combination (VS-6766, abemaciclib, and fulvestrant) in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to find the safest dose and see if the drugs can shrink tumors or stop them from growing. About 63 participants wi…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated May 26, 2026 02:14 UTC
-
Can a diabetes drug help breast cancer patients shed pounds and fight recurrence?
Disease control Recruiting nowThis study is testing whether tirzepatide, a drug used for weight loss, can help people with early-stage hormone-positive breast cancer lose at least 5% of their body weight during their regular cancer treatment. About 40 participants will take the drug and be monitored for safet…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
New hope for hard-to-treat breast cancer: experimental combo enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395) to adults with HR+/HER2- breast cancer that has sprea…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study tests whether adding elacestrant to standard chemotherapy (capecitabine) can help people with advanced estrogen receptor-positive (ER+) breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to get either the combi…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy aims to improve control of advanced breast cancer
Disease control Recruiting nowThis study tests different doses of the drug abemaciclib given together with radiation therapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has spread to the bone. The goal is to find the safest dose of abemaciclib when used alongside stand…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Triple-Drug cocktail shows promise for advanced breast cancer
Disease control Recruiting nowThis study tests a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) in 20 people with a common type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how well the treatment shrinks or controls the cancer. Participants either have new…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Blood test may spare thousands of breast cancer patients from chemo
Disease control Recruiting nowThis study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can a second targeted drug still work after the first fails? new trial hopes to find out
Disease control Recruiting nowThis study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Can a vaginal moisturizer ease breast cancer side effects?
Symptom relief Recruiting nowThis study tests whether Revaree Plus, a vaginal moisturizer, can improve vaginal dryness in women with hormone-receptor-positive breast cancer. About 60 participants who have completed primary cancer therapy or are on maintenance treatment will use the product for 8 weeks. The g…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 12, 2026 13:39 UTC
-
Could your gut bacteria predict a common cancer drug side effect?
Knowledge-focused Recruiting nowThis study looks at why some breast cancer patients get diarrhea from the drug Abemaciclib while others don't. Researchers will compare the gut bacteria of 60 women who have diarrhea with those who don't, using stool samples. The goal is to find if certain bacteria protect agains…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC
-
Blood test may predict when breast cancer treatment fails
Knowledge-focused Recruiting nowThis study is testing a blood test called DiviTum TKa to see if it can predict when hormone-receptor-positive (HR+) metastatic breast cancer stops responding to treatment. About 100 people starting standard therapies (endocrine therapy with or without a CDK4/6 inhibitor) will giv…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC
-
Brain scans for silent metastases: a new screening strategy for advanced breast cancer
Knowledge-focused Recruiting nowThis study is testing whether regular brain MRIs can detect cancer that has spread to the brain in people with stage IV breast cancer who have no brain symptoms. About 170 participants with different breast cancer subtypes will get brain scans at the start and again at 6 months o…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC